<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03025074</url>
  </required_header>
  <id_info>
    <org_study_id>Biobank Blood</org_study_id>
    <nct_id>NCT03025074</nct_id>
  </id_info>
  <brief_title>Blood Collection Biorepository for Liver Disease Research</brief_title>
  <official_title>Virology, Immunology and Mechanisms of Liver Disease in Patients With Hepatitis C and Other Liver Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of establishing a biorepository is to provide high quality specimens (serum,
      plasma, buffy coat and liver tissue) for future researchers who are studying the effects that
      fatty liver and viral diseases have on the liver.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Biorepository at the University at Buffalo has been established to collect biological
      samples from patients with various types of liver disease. The objectives of this
      biorepository are to stimulate collaboration between clinicians and researchers, to bolster
      training of junior investigators and to promote multidisciplinary integration to advance
      translational medicine and to improve the health of patients all over the country. The
      purpose of this biorepository is to support investigators and to provide them with high
      quality specimens to promote their efforts in new discoveries or perfecting treatment of
      patients with liver diseases caused by Non-Alcoholic Fatty Liver Disease (NAFLD),
      Non-Alcoholic Steatohepatitis (NASH), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and
      Human Immunodeficiency Virus (HIV). The goal is to obtain samples that represent patients
      seen in the clinics of medical centers in Western NY and from some of the rarer diseases
      encountered in these clinics. The ultimate goal is to develop the biorepository as Western
      New York's resource for clinically annotated human samples that can be used to conduct
      research that could lead to significant advances in patient care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2099</completion_date>
  <primary_completion_date type="Anticipated">December 2099</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Number of samples collected</measure>
    <time_frame>52 weeks</time_frame>
    <description>Total number of samples collected</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Non-Alcoholic Steatohepatitis(NASH)</condition>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis B</condition>
  <condition>Fibrosis</condition>
  <condition>Cirrhosis</condition>
  <condition>Fatty Liver</condition>
  <condition>Obesity, Childhood</condition>
  <condition>Bariatric Surgery Candidate</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, Plasma, Buffy Coat, Liver tissue (Core Needle Biopsy)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with NASH, NAFLD, Fibrosis, Cirrhosis, Hepatitis B or C, HIV or any form of Liver
        Disease.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  This protocol is to establish a biobank of blood samples from individuals with or
             without liver diseases including viral hepatitis, liver cancer, NASH, and negative
             control samples.

          -  Children and teenagers will be special populations considered in this protocol.

        Exclusion Criteria:

          -  Vulnerable populations such as adults unable to consent, infants, pregnant women or
             prisoners will not be considered for this research study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Talal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Bauer, BA</last_name>
    <phone>716-888-4825</phone>
    <email>bmbauer@buffalo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heidi NIeves-McGrath, BSN</last_name>
    <phone>716-888-4739</phone>
    <email>hnievesm@buffalo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University at Buffalo, Buffalo General Medical Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Bauer, BA</last_name>
      <phone>716-888-4825</phone>
      <email>bmbauer@buffalo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zeremski M, Sylvester C, Talal AH. Response to Commentary on Zeremski et al. (2016): Improvements in HCV-related Knowledge Among Substance Users on Opioid Agonist Therapy After an Educational Intervention. J Addict Med. 2016 Sep-Oct;10(5):364-5. doi: 10.1097/ADM.0000000000000240.</citation>
    <PMID>27685683</PMID>
  </reference>
  <reference>
    <citation>Juluru K, Talal AH, Yantiss RK, Spincemaille P, Weidman EK, Giambrone AE, Jalili S, Sourbron SP, Dyke JP. Diagnostic accuracy of intracellular uptake rates calculated using dynamic Gd-EOB-DTPA-enhanced MRI for hepatic fibrosis stage. J Magn Reson Imaging. 2017 Apr;45(4):1177-1185. doi: 10.1002/jmri.25431. Epub 2016 Aug 16.</citation>
    <PMID>27527820</PMID>
  </reference>
  <reference>
    <citation>Zeremski M, Dimova RB, Pillardy J, de Jong YP, Jacobson IM, Talal AH. Fibrosis Progression in Patients With Chronic Hepatitis C Virus Infection. J Infect Dis. 2016 Oct 15;214(8):1164-70. doi: 10.1093/infdis/jiw332. Epub 2016 Aug 2.</citation>
    <PMID>27485356</PMID>
  </reference>
  <reference>
    <citation>Ocque AJ, Hagler CE, Difrancesco R, Woolwine-Cunningham Y, Bednasz CJ, Morse GD, Talal AH. Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver. Bioanalysis. 2016 Jul;8(13):1353-63. doi: 10.4155/bio-2016-0040. Epub 2016 Jun 9.</citation>
    <PMID>27277877</PMID>
  </reference>
  <reference>
    <citation>Zeremski M, Zavala R, Dimova RB, Chen Y, Kritz S, Sylvester C, Brown LS Jr, Talal AH. Improvements in HCV-related Knowledge Among Substance Users on Opioid Agonist Therapy After an Educational Intervention. J Addict Med. 2016 Mar-Apr;10(2):104-9. doi: 10.1097/ADM.0000000000000196.</citation>
    <PMID>26881485</PMID>
  </reference>
  <reference>
    <citation>Bednasz CJ, Sawyer JR, Martinez A, Rose PG, Sithole SS, Hamilton HR, Kaufman FS, Venuto CS, Ma Q, Talal A, Morse GD. Recent advances in management of the HIV/HCV coinfected patient. Future Virol. 2015;10(8):981-997.</citation>
    <PMID>26877758</PMID>
  </reference>
  <reference>
    <citation>Cloherty G, Talal A, Coller K, Steinhart C, Hackett J Jr, Dawson G, Rockstroh J, Feld J. Role of Serologic and Molecular Diagnostic Assays in Identification and Management of Hepatitis C Virus Infection. J Clin Microbiol. 2016 Feb;54(2):265-73. doi: 10.1128/JCM.02407-15. Epub 2015 Dec 9. Review.</citation>
    <PMID>26659219</PMID>
  </reference>
  <reference>
    <citation>Zeremski M, Dimova RB, Benjamin S, Penney MS, Botfield MC, Talal AH. Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin. J Infect Dis. 2015 Jun 1;211(11):1795-9. doi: 10.1093/infdis/jiu807. Epub 2014 Dec 15.</citation>
    <PMID>25512630</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2017</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York at Buffalo</investigator_affiliation>
    <investigator_full_name>Andrew Talal</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Liver Disease</keyword>
  <keyword>Obesity</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>HIV</keyword>
  <keyword>Hepatology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Biorepository was created to provide high quality specimens to future researchers to advance their clinical and translational research.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

